Literature DB >> 19184104

Alpha-fetoprotein and human telomerase reverse transcriptase mRNA levels in peripheral blood of patients with hepatocellular carcinoma.

Sun-Young Kong1, Joong-Won Park, Jin Oak Kim, Nam Oak Lee, Jung An Lee, Kyung Woo Park, Eun Kyung Hong, Chang-Min Kim.   

Abstract

PURPOSE: Tumor-associated gene expression in peripheral blood reflects the presence of circulating hepatocellular carcinoma (HCC) cells and might be associated with aggressive features of HCC. We assessed the prognostic significance of alpha-fetoprotein (AFP) and human telomerase reverse transcriptase protein (hTERT) mRNA expression in the peripheral blood of HCC patients.
METHODS: About 343 HCC patients, treated at the National Cancer Center, Korea, were included in this study. We measured AFP and hTERT mRNA levels in peripheral blood using quantitative real-time reverse transcription polymerase chain reaction. The association between the expression of each gene and survival was analyzed.
RESULTS: AFP and hTERT mRNA were detected in 204 (59.5%) and 48 (14.0%) patients with HCC, respectively. The mean AFP copy number was 203 copies/microL (range 0-19992 copies/microL) and that of hTERT was 26 copies/microL (0-1711 copies/microL). AFP mRNA expression was correlated with the number of tumors (P = 0.05), but there were no significant association between hTERT expression and clinical features. There was also no relationship between overall survival and AFP (P = 0.08) or hTERT (P = 0.67) mRNA expression.
CONCLUSIONS: This is the first report to evaluate the association between peripheral blood hTERT mRNA expression, and survival of HCC patients. The results indicate that AFP and hTERT mRNA expression in peripheral blood may not be useful HCC prognostic markers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19184104     DOI: 10.1007/s00432-009-0549-9

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  21 in total

Review 1.  Telomeres and telomerase: new targets for the treatment of liver cirrhosis and hepatocellular carcinoma.

Authors:  André Lechel; Michael P Manns; K Lenhard Rudolph
Journal:  J Hepatol       Date:  2004-09       Impact factor: 25.083

2.  Hematogenous spreading of hepatocellular carcinoma cells: possible participation in recurrence in the liver.

Authors:  N O Funaki; J Tanaka; S I Seto; T Kasamatsu; T Kaido; M Imamura
Journal:  Hepatology       Date:  1997-03       Impact factor: 17.425

3.  Low abundance of telomerase in yeast: implications for telomerase haploinsufficiency.

Authors:  Amy D Mozdy; Thomas R Cech
Journal:  RNA       Date:  2006-08-07       Impact factor: 4.942

4.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

5.  Circulating tumor cell mRNAs in peripheral blood from hepatocellular carcinoma patients under radiotherapy, surgical resection or chemotherapy: a quantitative evaluation.

Authors:  I H Wong; W Yeo; T Leung; W Y Lau; P J Johnson
Journal:  Cancer Lett       Date:  2001-06-26       Impact factor: 8.679

6.  Prospective evaluation of circulating hepatocytes by alpha-fetoprotein mRNA in humans during liver surgery.

Authors:  A Lemoine; T Le Bricon; M Salvucci; D Azoulay; P Pham; J Raccuia; H Bismuth; B Debuire
Journal:  Ann Surg       Date:  1997-07       Impact factor: 12.969

7.  Quantitative real-time RT-PCR analysis of NY-ESO-1 and LAGE-1a mRNA expression in normal tissues and tumors, and correlation of the protein expression with the mRNA copy number.

Authors:  Shuichiro Sato; Yuji Noguchi; Hisashi Wada; Shoichiro Fujita; Shinichiro Nakamura; Ryo Tanaka; Tetsuya Nakada; Kosei Hasegawa; Kazuhiko Nakagawa; Fumihito Koizumi; Toshiro Ono; Kazuhiro Nouso; Achim Jungbluth; Yao-Tseng Chen; Lloyd J Old; Yasushi Shiratori; Eiichi Nakayama
Journal:  Int J Oncol       Date:  2005-01       Impact factor: 5.650

8.  Clinical significance of alpha-fetoprotein mRNA in blood of patients with hepatocellular carcinoma.

Authors:  Umberto Cillo; Filippo Navaglia; Alessandro Vitale; Alfiero Molari; Daniela Basso; Marco Bassanello; Alberto Brolese; Giacomo Zanus; Umberto Montin; Francesco D'Amico; Francesco Antonio Ciarleglio; Amedeo Carraro; Alessio Bridda; Patrizia Burra; Paolo Carraro; Mario Plebani; Davide Francesco D'Amico
Journal:  Clin Chim Acta       Date:  2004-09       Impact factor: 3.786

9.  Sensitive detection of human telomerase reverse transcriptase mRNA in the serum of patients with hepatocellular carcinoma.

Authors:  N Miura; G Shiota; T Nakagawa; Y Maeda; A Sano; A Marumoto; Y Kishimoto; Y Murawaki; J Hasegawa
Journal:  Oncology       Date:  2003       Impact factor: 2.935

10.  Highly-sensitive identification of alpha-fetoprotein mRNA in circulating peripheral blood of hepatocellular carcinoma patients.

Authors:  N Funaki; J Tanaka; S Seto; T Kasamatsu; T Kaido; M Imamura
Journal:  Life Sci       Date:  1995       Impact factor: 5.037

View more
  7 in total

Review 1.  Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation.

Authors:  Umberto Cillo; Tommaso Giuliani; Marina Polacco; Luz Maria Herrero Manley; Gino Crivellari; Alessandro Vitale
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

2.  Circulating tumor cells are associated with poor outcomes in early-stage hepatocellular carcinoma: a prospective study.

Authors:  Yeonjung Ha; Tae Hun Kim; Jae Eul Shim; Sunghyun Yoon; Mi Jung Jun; Young-Ho Cho; Han Chu Lee
Journal:  Hepatol Int       Date:  2019-11-05       Impact factor: 6.047

3.  Circulating tumor cells measurements in hepatocellular carcinoma.

Authors:  Franck Chiappini
Journal:  Int J Hepatol       Date:  2012-05-28

Review 4.  Clinical applications of liquid biopsy as prognostic and predictive biomarkers in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA.

Authors:  Jie Li; Xu Han; Xiaona Yu; Zongzhen Xu; Guangsheng Yang; Bingqi Liu; Peng Xiu
Journal:  J Exp Clin Cancer Res       Date:  2018-09-03

Review 5.  The Role of Liquid Biopsy in Hepatocellular Carcinoma Prognostication.

Authors:  Ismail Labgaa; Augusto Villanueva; Olivier Dormond; Nicolas Demartines; Emmanuel Melloul
Journal:  Cancers (Basel)       Date:  2021-02-06       Impact factor: 6.639

Review 6.  Liquid biopsy in patients with hepatocellular carcinoma: Circulating tumor cells and cell-free nucleic acids.

Authors:  Wataru Okajima; Shuhei Komatsu; Daisuke Ichikawa; Mahito Miyamae; Takuma Ohashi; Taisuke Imamura; Jun Kiuchi; Keiji Nishibeppu; Tomohiro Arita; Hirotaka Konishi; Atsushi Shiozaki; Ryo Morimura; Hisashi Ikoma; Kazuma Okamoto; Eigo Otsuji
Journal:  World J Gastroenterol       Date:  2017-08-21       Impact factor: 5.742

7.  Clinical value of circulating tumor cells for the diagnosis and prognosis of hepatocellular carcinoma (HCC): A systematic review and meta-analysis.

Authors:  Kai Cui; Yang Ou; Yangyang Shen; Sheng Li; Ziqiang Sun
Journal:  Medicine (Baltimore)       Date:  2020-10-02       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.